Tag: DOACs

cancer patient

Mayo Clinic study provides clarity on use of anticoagulants to treat...

A study by Mayo Clinic researchers provides some clarity on the use of direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, to treat...

What an interventionalist needs to know about DOACs in 2021

The publication of positive new data and a need to minimise hospital visits during the COVID-19 pandemic has seen a general trend towards using...
cancer patient

DOACs show promise over heparin injections in meta-analysis comparing cancer-associated VTE...

A recent meta-analysis found that direct oral anticoagulants (DOACs) appear to be a “reasonable alternative” to low molecular weight heparin (LMWH) for the treatment...
reduced hospital time and costs Xarelto

Direct anticoagulant for pulmonary embolism associated with reduced hospital time and...

New data from the MERCURY PE study have shown that patients with low-risk pulmonary embolism who were treated with the direct oral anticoagulant rivaroxaban,...
reduced hospital time and costs Xarelto

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...